Treatment of chronic lymphocytic leukemia with genetically targeted autologous t cells: Case report of an unforeseen adverse event in a phase i clinical trial

Molecular Therapy

Volumn 18, Issue 4, 2010, Pages 666-668

  Brentjens, Renier ^a   Yeh, Raymond ^a   Bernal, Yvette ^a   Riviere, Isabelle ^a   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTOKINE; FLUDARABINE; LYMPHOCYTE ANTIGEN RECEPTOR; MITOXANTRONE; PENTOSTATIN; PIPERACILLIN PLUS TAZOBACTAM; RITUXIMAB;

AGED; ANAMNESIS; AUTOPSY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DISEASE COURSE; DRUG MEGADOSE; GENE TARGETING; HUMAN; HUMAN TISSUE; HYPOTENSION; LETTER; LEUKAPHERESIS; LYMPHADENOPATHY; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFUSION; MALE; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE; TUMOR CELL DESTRUCTION;

EID: 77950480974     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.31     Document Type: Letter

References (6)

1. Sadelain, M, Rivière, I and Brentjens, R (2003). Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 3: 35-45. (Pubitemid 37328885)
2. Brentjens, RJ, Latouche, JB, Santos, E, Marti, F, Gong, MC, Lyddane, C et al. (2003). Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9: 279-286. (Pubitemid 36362782)
3. Maher, J, Brentjens, R, Gunset, G, Rivière, I and Sadelain, M (2002). Human T-lymphocyte cytotoxic-ity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 20: 70-75. (Pubitemid 34044918)
4. Brentjens, RJ, Santos, E, Nikhamin, Y, Yeh, R, Matsushita, M, La Perle, K et al. (2007). Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 13: 5426-5435. (Pubitemid 47510370)
5. Sadelain, M, Brentjens, R and Rivière, I (2009). The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 21: 215-223.
6. Hollyman, D, Stefanski, J, Przybylowski, M, Bartido, S, Borquez-Ojeda, O, Taylor, C et al. (2009). Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 32: 169-180.